ENLIVEX THERAPEUTICS LTD (ENLV) Stock Analyst Earnings Estimates
NASDAQ:ENLV - Nasdaq - IL0011319527 - Common Stock - Currency: USD
Full estimates are only available for subscribed users, you can see which data is available below.
Subscribed users also see more surprise data, now it is restricted to 4 quarters.
Examples of complete estimate data are available for MSFT and AAPL.
Registered users have access to more data. Please register or login for additional estimates and surprises .
| 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A 187.09% | N/A 81.60% | N/A 75.51% | |||||||||||
| EBITDA YoY % growth | -7.07M | -15.46M -118.67% | -15.83M -2.39% | -5.95M 62.41% | -2.11M 64.54% | -8.41M -298.58% | -9.5M -12.96% | -18.74M -97.26% | -25.02M -33.51% | -24.316M 2.81% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -7.08M | -15.48M -118.64% | -15.87M -2.52% | -5.96M 62.44% | -2.11M 64.60% | -8.62M -308.53% | -9.79M -13.57% | -19.29M -97.04% | -25.8M -33.75% | -25.151M 2.52% | N/A 41.04% | N/A 3.70% | N/A -92.86% | N/A -37.04% | N/A -25.51% | N/A 157.22% | N/A 582.78% | N/A 103.53% | N/A 85.67% | |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EPS YoY % growth | N/A | -42.40 -105.79% | -40.40 4.72% | N/A | N/A | N/A | -0.89 17.68% | N/A 1.44% | -1.69 -92.66% | -1.56 7.69% | N/A 55.87% | N/A 14.07% | N/A -1.72% | N/A -32.20% | N/A -20.51% | N/A 150.00% | N/A 478.72% | N/A 71.32% | N/A 65.67% |
All data in USD
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.16 67.06% | -0.16 25.82% | -0.16 -2.00% | -0.14 -19.00% | -0.13 16.13% |
| Revenue Q2Q % growth | N/A | N/A | N/A | N/A | |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -3.722M 38.89% | N/A | N/A | N/A | N/A |
All data in USD
| Period | Reported | Estimate | Difference | Surprise |
|---|---|---|---|---|
| Q3 2024 Q2Q % growth | -0.12 62.50% | -0.19 | 0.07 | 36.41% |
| Q2 2024 Q2Q % growth | -0.16 56.76% | -0.15 | -0.01 | -4.58% |
| Q1 2024 Q2Q % growth | -0.22 43.59% | -0.26 | 0.04 | 13.73% |
| Q4 2023 Q2Q % growth | -0.48 -23.08% | -0.29 | -0.19 | -68.07% |
| Q3 2023 Q2Q % growth | -0.32 -3.23% | -0.33 | 0.01 | 1.96% |
| Q2 2023 Q2Q % growth | -0.37 31.48% | -0.47 | 0.10 | 21.14% |
| Q1 2023 Q2Q % growth | -0.39 13.33% | -0.41 | 0.02 | 4.41% |
| Q4 2022 Q2Q % growth | -0.39 -36.55% | -0.39 | 0.00 | -0.62% |
| Q3 2022 Q2Q % growth | -0.31 -63.16% | -0.30 | -0.01 | -4.80% |
| Q2 2022 Q2Q % growth | -0.54 -217.65% | -0.46 | -0.08 | -17.65% |
| Q1 2022 Q2Q % growth | -0.45 -136.84% | -0.42 | -0.03 | -7.60% |
| Q4 2021 Q2Q % growth | 33.58% | -0.29 | % | |
| Q3 2021 Q2Q % growth | -0.19 -18.75% | -0.21 | 0.02 | 11.30% |
| Q2 2021 Q2Q % growth | -0.17 26.09% | -0.27 | 0.10 | 35.90% |
| Q1 2021 Q2Q % growth | -0.19 -171.43% | -0.21 | 0.02 | 11.30% |
| Q4 2020 Q2Q % growth | -0.43 -53.57% | -0.26 | -0.18 | -68.63% |
| Q3 2020 Q2Q % growth | -0.16 | -0.18 | 0.02 | 12.85% |
| Q2 2020 Q2Q % growth | -0.23 | -0.24 | 0.01 | 6.05% |
| Q1 2020 Q2Q % growth | -0.07 | -0.24 | 0.17 | 71.41% |
| Q4 2019 Q2Q % growth | -0.28 | -0.26 | -0.03 | -9.80% |
| Period | Reported | Estimate | Difference | Surprise |
|---|
| Next Q (1 month) | Next Q (3 month) | Next Year (1 month) | Next Year (3 month) | |
|---|---|---|---|---|
| EPS | 0% | 26.19% | 0% | 0% |
| Revenue | N/A | N/A | N/A | N/A |